Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1271-1277

  Kabasakal, Levent ^a   Demirci, Emre ^a   Ocak, Meltem ^b   Decristoforo, Clemens ^c   Araman, Ahmet ^b   Ozsoy, Yildiz ^b   Uslu, Ilhami ^a   Kanmaz, Bedii ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

68Ga DOTANOC; 68Ga DOTATATE; Neuroendocrine tumours; Octreotide; Somatostatin receptor

Indexed keywords

DOTA 1 NAI3 OCTREOTIDE GA 68; DOTA DEXTRO PHENYLALANINE TYROSINE 3 OCTREOTATE GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA DOTATATE; 68GA-DOTANOC; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; BRONCHUS TUMOR; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; GASTRINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS; IMAGE ANALYSIS; IMAGE QUALITY; MALE; MERKEL CELL TUMOR; MIXED ADENONEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PARAGANGLIOMA; POORLY DIFFIRENTIATED NEUROENDOCRINE CARCINOMA; SALIVARY GLAND; SCINTIGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; TUMOR DIFFERENTIATION; WELL DIFFIRENTIATED NEUROENDOCRINE TUMOR; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES;

EID: 84865471278     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2123-y     Document Type: Article

References (24)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
2. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997;70:530-7. (Pubitemid 27149636)
3. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010;42:220-5.
4. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Ejick CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
5. Srirajkanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPAoctreotide scintigraphy. J Nucl Med 2010;51:875-82.
6. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. Ga68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18. (Pubitemid 47571404)
7. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan). Mol Imaging Biol 2011;13:583-93.
8. Frilling A, Sotiropoulos C, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850-6.
9. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3- octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
10. Ambrossini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73.
11. Pettino C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-9. (Pubitemid 350234154)
12. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis fort he preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-5. (Pubitemid 47494113)
13. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010;31:1025-32.
14. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 2010;54:61-7.
15. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26:963-70. (Pubitemid 351398091)
16. Campana D, Ambrossini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010;51:353-9.
17. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation ofimmunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48-52.
18. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82. (Pubitemid 30167697)
19. Wild D, Schmitt JS, Ginj M, Mäcke H, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47. (Pubitemid 37247950)
20. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93. (Pubitemid 46919547)
21. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60. (Pubitemid 34028303)
22. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:1659-68.
23. Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006;13:52-60. (Pubitemid 43327555)
24. Basu S, Abhyankar A, Kand P, Kumar R, Asopa R, Rajan MG, et al. 'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. Nucl Med Commun 2011;32:654-8.